Alnylam Pharmaceuticals
ALNY
#660
Rank
ยฃ28.45 B
Marketcap
ยฃ213.09
Share price
-0.25%
Change (1 day)
-2.46%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): ยฃ2.84

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is ยฃ2.82. In 2025 the company made an earnings per share (EPS) of ยฃ1.34.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)ยฃ2.84112.22%
2025ยฃ1.34
2023-ยฃ2.63-62%
2022-ยฃ6.9229.03%
2021-ยฃ5.36-3.36%
2020-ยฃ5.55-8.48%
2019-ยฃ6.067.67%
2018-ยฃ5.6339.74%
2017-ยฃ4.0312.94%
2016-ยฃ3.5738.84%
2015-ยฃ2.57-32.88%
2014-ยฃ3.83259.44%
2013-ยฃ1.06-31.25%
2012-ยฃ1.55

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
ยฃ5.23 85.22%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
ยฃ1.91-32.46%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
ยฃ31.66 1,022.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-ยฃ6.19-319.53%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-ยฃ0.54-119.26%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-ยฃ0.18-106.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
ยฃ1.02-63.85%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
ยฃ0.26-90.77%๐Ÿ‡บ๐Ÿ‡ธ USA